EA201892264A1 - Производные тетрагидроизохинолина - Google Patents

Производные тетрагидроизохинолина

Info

Publication number
EA201892264A1
EA201892264A1 EA201892264A EA201892264A EA201892264A1 EA 201892264 A1 EA201892264 A1 EA 201892264A1 EA 201892264 A EA201892264 A EA 201892264A EA 201892264 A EA201892264 A EA 201892264A EA 201892264 A1 EA201892264 A1 EA 201892264A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
tetrahydroisoquinoline
pharmaceuticals
formulas
denotes
Prior art date
Application number
EA201892264A
Other languages
English (en)
Other versions
EA036137B1 (ru
Inventor
Али Атеш
Эрик Жнов
Лоран Провен
Анна Валад
Адриан Халл
Original Assignee
Юсб Байофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Байофарма Спрл filed Critical Юсб Байофарма Спрл
Publication of EA201892264A1 publication Critical patent/EA201892264A1/ru
Publication of EA036137B1 publication Critical patent/EA036137B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

В заявке описаны производные тетрагидроизохинолина формулы (I)в которой G обозначает конденсированную гетероциклическую систему, выбранную из числа групп, описывающихся формулами (G)-(G)которые являются позитивными аллостерическими модуляторами D1 и поэтому полезны для применения в качестве фармацевтических средств, предназначенных для лечения заболеваний, в которых играют роль рецепторы D1.
EA201892264A 2016-04-13 2017-04-07 Производные тетрагидроизохинолина EA036137B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16165012 2016-04-13
PCT/EP2017/058422 WO2017178377A1 (en) 2016-04-13 2017-04-07 Tetrahydroisoquinoline derivatives

Publications (2)

Publication Number Publication Date
EA201892264A1 true EA201892264A1 (ru) 2019-04-30
EA036137B1 EA036137B1 (ru) 2020-10-02

Family

ID=55745692

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892264A EA036137B1 (ru) 2016-04-13 2017-04-07 Производные тетрагидроизохинолина

Country Status (9)

Country Link
US (1) US10370355B2 (ru)
EP (1) EP3442945B1 (ru)
JP (1) JP6908623B2 (ru)
CN (1) CN108884050B (ru)
BR (1) BR112018070363A2 (ru)
CA (1) CA3018352A1 (ru)
EA (1) EA036137B1 (ru)
ES (1) ES2819841T3 (ru)
WO (1) WO2017178377A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
MX2021015872A (es) * 2019-07-01 2022-02-03 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
CA3139571A1 (en) * 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
IL303688A (en) * 2020-12-18 2023-08-01 UCB Biopharma SRL Amorphous solid dispersions
WO2022129268A1 (en) 2020-12-18 2022-06-23 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
WO2022129356A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
EP4263522A1 (en) 2020-12-18 2023-10-25 UCB Biopharma SRL Dihydroisoquinolinyl derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305641D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
HUP0402643A2 (hu) * 2001-12-19 2005-04-28 H. Lundbeck A/S 3,4-Dihidro-1H-izokinolin-2-il-származékok, eljárás az előállításukra és az ezeket tartalmazó gyógyszerkészítmények
ZA200701232B (en) * 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
KR20090127307A (ko) 2007-03-01 2009-12-10 얀센 파마슈티카 엔.브이. 히스타민 ｈ３ 수용체 조절제로서의 테트라하이드로이소퀴놀린 화합물
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
ES2397764T3 (es) * 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8367700B2 (en) * 2008-12-17 2013-02-05 Gruenenthal Gmbh Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EA035544B1 (ru) * 2014-10-08 2020-07-03 Юсб Байофарма Спрл Производные тетрагидроизохинолина
EP3204374B1 (en) 2014-10-08 2019-04-03 UCB Biopharma SPRL Isoindoline derivatives

Also Published As

Publication number Publication date
CN108884050B (zh) 2022-07-05
EP3442945B1 (en) 2020-07-08
CA3018352A1 (en) 2017-10-19
EP3442945A1 (en) 2019-02-20
BR112018070363A2 (pt) 2019-01-29
JP6908623B2 (ja) 2021-07-28
EA036137B1 (ru) 2020-10-02
ES2819841T3 (es) 2021-04-19
CN108884050A (zh) 2018-11-23
JP2019513792A (ja) 2019-05-30
US20190106406A1 (en) 2019-04-11
US10370355B2 (en) 2019-08-06
WO2017178377A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
EA201892264A1 (ru) Производные тетрагидроизохинолина
EA201790785A1 (ru) Производные тетрагидроизохинолина
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
BR112014013974A2 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
EA201691302A1 (ru) Новые гетероциклические соединения
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
BR112019025049A2 (pt) Anéis 6- 5 fundidos como inibidores de c5a
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201992679A1 (ru) N-замещенные индольные производные
EA201790570A1 (ru) Модуляторы р2х7
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM